Department of Neurology, Erasmus Medical Center, Rotterdam, The Netherlands.
J Proteome Res. 2011 Apr 1;10(4):2006-10. doi: 10.1021/pr101221h. Epub 2011 Feb 22.
Increased plasma levels of clusterin have recently been found to be associated with severity and progression in Alzheimer's disease (AD). We have investigated clusterin levels in serum of elderly people with presymptomatic AD from a population-based prospective cohort study. During 10 years follow-up, 43 participants were diagnosed with AD after on average 4.2 years (±2.6 years SD) after the initial blood sampling. At the time of blood sampling, these participants showed normal cognitive function. For each presymptomatic AD case, a control was matched on gender and age. Furthermore, the selected controls had to remain dementia-free and still be alive at the end of follow-up. Quantitative serum clusterin levels were measured with a newly developed multiple reaction monitoring (MRM) assay. Results of the assay showed no significant difference in clusterin levels between presymptomatic AD and controls (p-value 0.54). In conclusion, serum clusterin is not an early, presymptomatic biomarker for AD.
最近发现，血浆中聚集素水平的升高与阿尔茨海默病（AD）的严重程度和进展有关。我们研究了来自基于人群的前瞻性队列研究中处于无症状 AD 的老年人的血清中聚集素水平。在 10 年的随访期间，43 名参与者在最初采血后平均 4.2 年（±2.6 年 SD）后被诊断为 AD。在采血时，这些参与者表现出正常的认知功能。对于每个无症状 AD 病例，根据性别和年龄匹配一个对照。此外，所选对照者必须在随访结束时仍然无痴呆且存活。使用新开发的多重反应监测（MRM）测定法测量定量血清聚集素水平。该测定法的结果显示，无症状 AD 患者和对照组之间的聚集素水平没有显著差异（p 值 0.54）。总之，血清聚集素不是 AD 的早期、无症状生物标志物。
